Under the terms of the agreement, Orchid is eligible to receive payments totaling more than US$ 100 million associated with the achievement of various research and development milestones involving multiple candidates. Orchid is also eligible to receive significant royalties on worldwide net sales of any products commercialized under the agreement.
